1. BennRT. Some mathematical properties of weight‐for‐height indices used as measures of adiposity. Br J Prev Soc Med1971;25:42.

2. TroianoRP, FrongilloEAJr, SobalJ, et al.The relationship between body weight and mortality: a quantitative analysis of combined information from existing studies. Int J Obes Relat Metab Disord1996;20:63.

3. JanssenI, KatzmarzykPT, RossR. Waist circumference and not body mass index explains obesity‐related health risk. Am J Clin Nutr2004;79:379.

4. World Health Organization. Obesity: preventing and managing the global epidemic. Report of a WHO consultation on obesity, 2000.

5. OgdenCL, CarrollMD, KitBK, et al.Prevalence of obesity in the United States, 2009–2010, NCHS data brief, no 82. Hyattsville, MD: National Center for Health Statistics; 2012.

6. FlegalKM, CarrollMD, KitBK, et al.Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999–2010. JAMA2012;307:491. CrossRef

7. OgdenCL, LambMM, CarrollMD, et al.Obesity and socioeconomic status in adults: United States, 2005–2008, NCHS data brief, no 82. Hyattsville, MD: National Center for Health Statistics; 2012.

8. FlegalK, GraubardB, WilliamsonD, et al.Excess deaths associated with underweight, overweight, and obesity. JAMA2005;293:1861. CrossRef

9. OlshanskySJ, PassaroD, HershowR, et al.A potential decline in life expectancy in the United States in the 21st century. N Engl J Med2005;352:1138. CrossRef

10. FinkelsteinEA, TrogdonJG, CohenJW, et al.Annual medical spending attributable to obesity: payer‐and service‐specific estimates. Health Aff (Millwood)2009;28:w822. CrossRef

11. OgdenCL, CarrollMD, CurtinLR, et al.Prevalence of high body mass index in U.S. children and adolescents, 2007–2008. JAMA2010;303:242. CrossRef

12. World Health Organization. Global Health Observatory. Obesity: situation and trends, 2013. Available at: http://www.who.int/gho/ncd/risk_factors/obesity_text/en/index.html.

13. ChagnonYC, RankinenT, SnyderEE, et al.The human obesity gene map: the 2002 update. Obes Res2003;11:313. CrossRef

14. PowerC, JefferisBJ. Fetal environment and subsequent obesity: a study of maternal smoking. Int J Epidemiol2002;31:413. CrossRef

15. DabeleaD, HansonRL, LindsayRS, et al.Intrauterine exposure to diabetes conveys risks for type 2 diabetes and obesity: a study of discordant sibships. Diabetes2000;49:2208. CrossRef

16. HarderT, BergmannR, KallischniggG, et al.Duration of breastfeeding and risk of overweight: a meta‐analysis. Am J Epidemiol2005;162:397. CrossRef

17. PrenticeAM, JebbSA. Obesity in Britain: gluttony or sloth?BMJ1995;311:437. CrossRef

18. WilliamsonDF, MadansJ, AndaRF, et al.Recreational physical activity and ten‐year weight change in a US national cohort. Int J Obes Relat Metab Disord1993;17:279.

19. SwinburnBA, SacksG, HallKD, et al.The global obesity pandemic: shaped by global drivers and local environments. Lancet2011;378:804. CrossRef

20. DhurandharNV, KulkarniPR, AjinkyaSM, et al.Association of adenovirus infection with human obesity. Obes Res1997;5:464. CrossRef

21. StraderAD, WoodsSC. Gastrointestinal hormones and food intake. Gastroenterology2005;128:175. CrossRef

22. BadmanMK, FlierJS. The gut and energy balance: visceral allies in the obesity wars. Science2005;307:1909. CrossRef

23. LundgrenO. Interface between the intestinal environment and the nervous system. Gut2004;53(Suppl 2):16. CrossRef

24. DouglasBR, JansenJB, de JongAJ, et al.Effect of various triglycerides on plasma cholecystokinin levels in rats. J Nutr1990;120:686.

25. MoranTH, LadenheimEE, SchwartzGJ. Within‐meal gut feedback signaling. Int J Obes Relat Metab Disord2001;25(Suppl 5):39. CrossRef

26. MoranTH, SchwartzGJ. Neurobiology of cholecystokinin. Crit Rev Neurobiol1994;9:1.

27. GreeleyGHJr, HashimotoT, IzukuraM, et al.A comparison of intraduodenally and intracolonically administered nutrients on the release of peptide‐YY in the dog. Endocrinology1989;125:1761. CrossRef

28. BatterhamRL, CowleyMA, SmallCJ, et al.Gut hormone PYY(3‐36) physiologically inhibits food intake. Nature2002;418:650. CrossRef

29. BatterhamRL, CohenMA, EllisSM, et al.Inhibition of food intake in obese subjects by peptide YY3‐36. N Engl J Med2003;349:941. CrossRef

30. AsakawaA, InuiA, YuzurihaH, et al.Characterization of the effects of pancreatic polypeptide in the regulation of energy balance. Gastroenterology2003;124:1325. CrossRef

31. BatterhamRL, Le RouxCW, CohenMA, et al.Pancreatic polypeptide reduces appetite and food intake in humans. J Clin Endocrinol Metab2003;88:3989. CrossRef

32. BrubakerPL, AniniY. Direct and indirect mechanisms regulating secretion of glucagon‐like peptide‐1 and glucagon‐like peptide‐2. Can J Physiol Pharmacol2003;81:1005. CrossRef

33. GutzwillerJP, GokeB, DreweJ, et al.Glucagon‐like peptide‐1: a potent regulator of food intake in humans. Gut1999;44:81. CrossRef

34. GutzwillerJP, DreweJ, GokeB, et al.Glucagon‐like peptide‐1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am J Physiol1999;276:1541.

35. NaslundE, BarkelingB, KingN, et al.Energy intake and appetite are suppressed by glucagon‐like peptide‐1 (GLP‐1) in obese men. Int J Obes Relat Metab Disord1999;23:304. CrossRef

36. Delgado‐ArosS, KimDY, BurtonDD, et al.Effect of GLP‐1 on gastric volume, emptying, maximum volume ingested, and postprandial symptoms in humans. Am J Physiol2002;282:424.

37. CohenMA, EllisSM, Le RouxCW, et al.Oxyntomodulin suppresses appetite and reduces food intake in humans. J Clin Endocrinol Metab2003;88:4696. CrossRef

38. LutzTA, Del PreteE, ScharrerE. Reduction of food intake in rats by intraperitoneal injection of low doses of amylin. Physiol Behav1994;55:891. CrossRef

39. LutzTA, GearyN, SzabadyMM, et al.Amylin decreases meal size in rats. Physiol Behav1995;58:1197. CrossRef

40. SchmitzO, BrockB, RungbyJ. Amylin agonists: a novel approach in the treatment of diabetes. Diabetes2004;53(Suppl 3):233. CrossRef

41. FlierJS. Obesity wars: molecular progress confronts an expanding epidemic. Cell2004;116:337. CrossRef

42. SobhaniI, BadoA, VissuzaineC, et al.Leptin secretion and leptin receptor in the human stomach. Gut2000;47:178. CrossRef

43. ElmquistJK, EliasCF, SaperCB. From lesions to leptin: hypothalamic control of food intake and body weight. Neuron1999;22:221. CrossRef

44. SaadMF, Riad‐GabrielMG, KhanA, et al.Diurnal and ultradian rhythmicity of plasma leptin: effects of gender and adiposity. J Clin Endocrinol Metab1998;83:453.

45. AsakawaA, InuiA, KagaT, et al.Ghrelin is an appetite‐stimulatory signal from stomach with structural resemblance to motilin. Gastroenterology2001;120:337. CrossRef

46. CummingsDE, PurnellJQ, FrayoRS, et al.A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes2001;50:1714. CrossRef

47. CummingsDE, WeigleDS, FrayoRS, et al.Plasma ghrelin levels after diet‐induced weight loss or gastric bypass surgery. N Engl J Med2002;346:1623. CrossRef

48. SpitzerRL, DevlinM, WalshBT. Binge eating disorder: a multisite field trial of the diagnostic criteria. Int J Eat Disord1992;11:191. CrossRef

49. LarssonB, SvardsuddK, WelinL, et al.Abdominal adipose tissue distribution, obesity, and risk of cardiovascular disease and death: 13 year follow up of participants in the study of men born in 1913. BMJ1984;288:1401. CrossRef

50. RichardsonDW, VinikAI. Metabolic implications of obesity: before and after gastric bypass. Gastroenterol Clin North Am2005;34:9. CrossRef

51. IsomaaB, AlmgrenP, TuomiT, et al.Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care2001;24:683. CrossRef

52. El‐SeragHB. The epidemic of esophageal adenocarcinoma. Gastroenterol Clin North Am2002;31:421. CrossRef

53. Diaz‐RubioM, Moreno‐Elola‐OlasoC, ReyE, et al.Symptoms of gastro‐oesophageal reflux: prevalence, severity, duration and associated factors in a Spanish population. Aliment Pharmacol Ther2004;19:95. CrossRef

54. LockeGRIII, TalleyNJ, FettSL, et al.Risk factors associated with symptoms of gastroesophageal reflux. Am J Med1999;106:642. CrossRef

55. MurrayL, JohnstonB, LaneA, et al.Relationship between body mass and gastrooesophageal reflux symptoms: the Bristol Helicobacter Project. Int J Epidemiol2003;32:645. CrossRef

56. LagergrenJ, BergstromR, NyrenO. No relation between body mass and gastrooesophageal reflux symptoms in a Swedish population‐based study. Gut2000;47:26. CrossRef

57. WuAH, TsengCC, BernsteinL. Hiatal hernia, reflux symptoms, body size, and risk of esophageal and gastric adenocarcinoma. Cancer2003;98:940. CrossRef

58. NilssonM, LundegardhG, CarlingL, et al.Body mass and reflux oesophagitis: an oestrogen‐dependent association?Scand J Gastroenterol2002;37:626. CrossRef

59. Stene‐LarsenG, WebergR, FroyshovLI, et al.Relationship of overweight to hiatus hernia and reflux oesophagitis. Scand J Gastroenterol1988;23:427. CrossRef

60. WilsonLJ, MaW, HirschowitzBI. Association of obesity with hiatal hernia and esophagitis. Am J Gastroenterol1999;94:2840. CrossRef

61. El‐SeragHB. Obesity and disease of the esophagus and colon. Gastroenterol Clin North Am2005;34:63. CrossRef

62. BrownLM, SwansonCA, GridleyG, et al.Adenocarcinoma of the esophagus: role of obesity and diet. J Natl Cancer Inst1995;87:104. CrossRef

63. ChowWH, BlotWJ, VaughanTL, et al.Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst1998;90:150. CrossRef

64. DugganC, OnstadL, HardikarS, et al.Association between markers of obesity and progression from barrett's esophagus to esophageal adenocarcinoma. Clin Gastroenterol Hepatol2013;11:934. doi: 10.1016/j.cgh.2013.02.017; NIHMSID: NIHMS451558. CrossRef

65. StampferMJ, MaclureKM, ColditzGA, et al.Risk of symptomatic gallstones in women with severe obesity. Am J Clin Nutr1992;55:652.

66. ErlingerS. Gallstones in obesity and weight loss. Eur J Gastroenterol Hepatol2000;12:1347. CrossRef

67. KodamaH, KonoS, TodorokiI, et al.Gallstone disease risk in relation to body mass index and waist‐to‐hip ratio in Japanese men. Int J Obes Relat Metab Disord1999;23:211. CrossRef

68. ReubenA, MatonPN, MurphyGM, et al.Bile lipid secretion in obese and non‐obese individuals with and without gallstones. Clin Sci1985;69:71. CrossRef

69. LowenfelsAB, MaisonneuveP, BoyleP, et al.Epidemiology of gallbladder cancerHepatogastroenterology1999;46:1529.

70. MartinezJ, Sanchez‐PayaJ, PalazonJM, et al.Obesity: a prognostic factor of severity in acute pancreatitis. Pancreas1999;19:15. CrossRef

71. YeoTP, LowenfelsAB. Demographics and epidemiology of pancreatic cancer. Cancer J2012;18:477. CrossRef

72. Berrington de GonzalezA, SweetlandS, SpencerE. A meta‐analysis of obesity and the risk of pancreatic cancer. Br J Cancer2003;89:519. CrossRef

73. HodgsonM, Van ThielDH, Goodman‐KleinB. Obesity and hepatotoxin risk factors for fatty liver disease. Br J Ind Med1991;48:690.

74. GiraudNS, BorottoE, AubertA, et al.Excess weight risk factor for alcoholic liver disease. Hepatology1997;25:108. CrossRef

75. GholamPM, KotlerDP, FlancbaumLJ. Liver pathology in morbidly obese patients undergoing Roux‐en‐Y gastric bypass surgery. Obes Surg2002;12:49. CrossRef

76. MarchesiniG, BugianesiE, ForlaniG, et al.Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology2003;37:917. CrossRef

77. AnaniaFA. Leptin, liver, and obese mice – fibrosis in the fat laneHepatology2002;36:246. CrossRef

78. MooreLL, BradleeML, SingerMR, et al.BMI and waist circumference as predictors of lifetime colon cancer risk in Framingham Study adults. Int J Obes Relat Metab Disord2004;28:559. CrossRef

79. BardouM, BarkunAN, MartelM. Obesity and colorectal cancer. Gut2013;62:933. CrossRef

80. GiovannucciE. Obesity, gender, and colon cancer. Gut2002;51:147. CrossRef

81. NeugutAI, LeeWC, GarbowskiGC, et al.Obesity and colorectal adenomatous polyps. J Natl Cancer Inst1991;83:359. CrossRef

82. CrowellMD, CheskinLJ, MusialF. Prevalence of gastrointestinal symptoms in obese and normal weight binge eatersAm J Gastroenterol1994;89:387.

83. National Heart, Lung, and Blood Institute, North American Association for the Study of Obesity. The practical guide: identification, evaluation, and treatment of overweight and obesity in adults. Bethesda, MD. (NIH publication no. 00‐4048.). 2000. Also available at http://www.nhlbi.nih.gov/guidelines/obesity/practgde.htm.

84. RosenbaumM, HirschJ, GallagherDA, et al.Long‐term persistence of adaptive thermogenesis in subjects who have maintained a reduced body weight. Am J Clin Nutr2008;88:906.

85. GoldsteinDJ. Beneficial health effects of modest weight loss. Int J Obes1992;16:397.

86. BalartLA. Diet options of obesity: fad or famous. Gastroenterol Clin North Am2005;34:83. CrossRef

87. HooperL, AbdelhamidA, MooreHJ, et al.Effect of reducing total fat intake on body weight: systematic review and meta‐analysis of randomised controlled trials and cohort studies. BMJ2012;345:e7666. doi: 10.1136/bmj.e7666; Review. CrossRef

88. FungTT, van DamRM, HankinsonSE, et al.Low‐carbohydrate diets and all‐cause and cause‐specific mortality: two cohort studies. Ann Intern Med2010;153:289. CrossRef

89. WaddenTA, FosterGD, LetiziaKA. One‐year behavioral treatment of obesity: Comparison of moderate and severe caloric restriction and the effects of weight maintenance therapy. J Consult Clin Psychol1994;62:165. CrossRef

90. TsaiAG, WaddenTA. The evolution of very‐low‐calorie diets: an update and meta‐analysis. Obesity (Silver Spring)2006;14:1283. CrossRef

91. HeymsfieldSB, van MierloCA, van der KnaapHC, et al.Weight management using a meal replacement strategy: meta and pooling analysis from six studies. Int J Obes Relat Metab Disord2003;27:537. CrossRef

92. DansingerML, GleasonJA, GriffithJL, et al.Comparison of the Atkins, Ornish, Weight Watchers, and Zone diets for weight loss and heart disease risk reduction: a randomized trial. JAMA2005;293:43. CrossRef

93. WingRR. Behavioral approaches to the tretment of obesity. In: BrayGA, BouchardC(eds). Handbook of Obesity. Clinical Applications. New York: Marcel Dekker, Inc; 2004: 147.

94. WeintraubM. Long‐term weight control study: conclusions. Clin Pharmacol Ther1992;51:642. CrossRef

95. BallingerA, PeikinSR. Orlistat: its current status as an anti‐obesity drug. Eur J Pharmacol2002;440:109. CrossRef

96. SjostromL, RissanenA, AndersenT, et al.Randomised placebo‐controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet1998;352:167. CrossRef

97. DavidsonMH, HauptmanJ, DiGirolamoM, et al.Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA1999;281:235. CrossRef

98. KaplanLM. Pharmacological therapies for obesity. Gastroenterol Clin North Am2005;34:91. CrossRef

99. ThurairajahPH, SynWK, NeilDA, et al.Orlistat (Xenical)‐induced subacute liver failure. Eur J Gastroenterol Hepatol2005;17:1437. CrossRef

100. MonteroJL, MuntaneJ, FragaE, et al.Orlistat associated subacute hepatic failure [Letter]. J Hepatol2001;34:173. CrossRef

101. SmithSR, WeissmanNJ, AndersonCM, et al.; Behavioral Modification and Lorcaserin for Overweight and Obesity Management (BLOOM) Study Group. Multicenter, placebo‐controlled trial of lorcaserin for weight management. N Engl J Med2010;363:245. CrossRef

102. FidlerMC, SanchezM, RaetherB, et al.; BLOSSOM Clinical Trial Group. A one‐year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab2011;96:3067. CrossRef

103. GaddeKM, AllisonDB, RyanDH, et al.Effects of low‐dose, controlled‐release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo‐controlled, phase 3 trial. Lancet2011;377:1341. CrossRef

104. Food and Drug Administration. QSYMIA. Risk evaluation and mitigation strategy (REMS). Available online at: http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM312598.pdf (Accessed on June 1st, 2013).

105. YanovskiSZ, YanovskiJA. Obesity. NEJM2002;346:591. CrossRef

106. JainAK, KaplanRA, GaddeKM, et al.Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms. Obes Res2002;10:1049. CrossRef

107. SaperRB, EisenbergDM, PhillipsRS. Common dietary supplements for weight loss. Am Fam Physician2004;70:1731.

108. AdamsTD, GressRE, SmithSC, et al.Long‐term mortality after gastric bypass surgery. N Engl J Med2007;357:753. CrossRef

109. MaggardMA, ShugarmanLR, SuttorpM, et al.Meta‐analysis: surgical treatment of obesity. Ann Intern Med2005;142:547. CrossRef

110. DemariaEJ, JamalMK. Surgical options for obesity. Gastroenterol Clin North Am2005;34:127. CrossRef

111. IonutV, BurchM, YoudimA, et al.Gastrointestinal hormones and bariatric surgery‐induced weight loss. Obesity (Silver Spring)2013;21:1093. CrossRef

112. SugermanHJ, LondreyGL, KellumJM, et al.Weight loss with vertical banded gastroplasty and Roux‐Y bypass for morbid obesity with selective versus random assignment. Am J Surg1989;157:93. CrossRef

113. HallJC, WattsJM, O'BrienPE, et al.Gastric surgery for morbid obesity. The Adelaide study. Ann Surg1990;211:419. CrossRef

114. MunEC, BlackburnGL, MatthewsJB. Current status of medical and surgical therapy for obesity. Gastroenterology2001;120:669. CrossRef

115. NguyenNT, GoldmanC, RosenquistCJ, et al.Laparoscopic versus open gastric bypass: a randomized study of outcomes, quality of life, and costs. Ann Surg2001;234:279. CrossRef

116. Asge Standards of Practice Committee. Role of endoscopy in the bariatric surgery patient. Gastrointest Endosc2008;68:1. CrossRef

117. MacLeanLD, RhodeBM, ForseRA. Late results of vertical banded gastroplasty for morbid and super obesity. Surgery1990;107:20.

118. RenCJ, HorganS, PonceJ. US experience with the LAP‐BAND system. Am J Surg2002;184:46. CrossRef

119. SpivakH, AnwarF, BurtonS, et al.The Lap‐Band system in the United States: one surgeon's experience with 271 patients. Surg Endosc2004;18:198. CrossRef

120. FoxSR, FoxKM, SrikanthMS, et al.The Lap‐Band system in a North American population. Obes Surg2003;13:275. CrossRef

121. HollowayJA, ForneyGA, GouldDE. The Lap‐Band is an effective tool for weight loss even in the United States. Am J Surg2004;188:659. CrossRef

122. O'BrienPE, MacDonaldL, AndersonM, et al.Long‐term outcomes after bariatric surgery: fifteen‐year follow‐up of adjustable gastric banding and a systematic review of the bariatric surgical literature. Ann Surg2013;257:87. CrossRef

123. HutterMM, SchirmerBD, JonesDB, et al.First report from the American College of Surgeons Bariatric Surgery Center Network: laparoscopic sleeve gastrectomy has morbidity and effectiveness positioned between the band and the bypass. Ann Surg2011;254:410. CrossRef

124. BeymerC, KowdleyKV, LarsonA, et al.Prevalence and predictors of asymptomatic liver disease in patients undergoing gastric bypass surgery. Arch Surg2003;138:1240. CrossRef

125. KaplanLM. Gastrointestinal management of the bariatric surgery patient. Gastroenterol Clin North Am2005;34:105. CrossRef

126. ThompsonCC. Endoscopic therapy of obesity: a new paradigm in bariatric care. Gastrointest Endosc2010;72:505. CrossRef

127. NiebenOG, HarboeH. Intragastric balloon as an artificial bezoar for treatment of obesity. Lancet1982;1:198. CrossRef

128. RyouM, RyanMB, ThompsonCC. Current status of endoluminal bariatric procedures for primary and revision indications. Gastrointest Endosc Clin N Am2011;21:315. CrossRef

129. ShiffmanML, SugermanHJ, KellumJM, et al.Gallstone formation after rapid weight loss: a prospective study in patients undergoing gastric bypass surgery for treatment of morbid obesity. Am J Gastroenterol1991;86:1000.

130. GebhardRL, PriggeWF, AnselHJ, et al.The role of gallbladder emptying in gallstone formation during diet induced rapid weight loss. Hepatology1996;24:544. CrossRef

131. ShiffmanML, SugermanHJ, KellumJM, et al.Changes in gallbladder bile composition following gallstone formation and weight reduction. Gastroenterology1992;103:214.

132. GustafssonU, BenthinL, GranstromL, et al.Changes in gallbladder bile composition and crystal detection time in morbidly obese subjects after bariatric surgery. Hepatology2005;41:1322. CrossRef

133. CalhounR, WillbanksO. Coexistence of gallbladder diseases and morbid obesity. Am J Surg1987;154:655. CrossRef

134. SugermanHJ, BrewerWH, ShiffmanML, et al.A multicenter, placebo‐controlled, randomized, double‐blind, prospective trial of prophylactic Ursodiol for the prevention of gallstone formation following gastricbypass‐induced rapid weight loss. Am J Surg1995;169:91. CrossRef

135. LuyckxF, DesaiveC, ThiryA, et al.Liver abnormalities in severely obese subjects: Effects of drastic weight loss after gastroplasty. Int J Obes1998;22:222. CrossRef

136. AndersenT, GluudC, FranzmannM, et al.Hepatic effects of dietary weight loss in morbidly obese subjects. J Hepatol1991;12:224. CrossRef

137. BlackburnG, MunE. Effects of weight loss surgeries on liver disease. Semin Liver Dis2004;24:371. CrossRef